Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome in Malignant Lymphoma
NCT02131688Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2013
- Primary completion
- Aug 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitoxantrone in malignant lymphoma, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Maximum Tolerated Dose at 4 months. Status: unknown.
02
Drugs
mitoxantrone
03
Conditions
malignant lymphoma
Beyond the preview
Go deeper on NCT02131688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02131688.